Back to Search
Start Over
Supplementary Table 1 from Phase 1 Open-Label, Multicenter Study of First-in-Class RORĪ³ Agonist LYC-55716 (Cintirorgon): Safety, Tolerability, and Preliminary Evidence of Antitumor Activity
- Publication Year :
- 2023
- Publisher :
- American Association for Cancer Research (AACR), 2023.
-
Abstract
- Pharmacokinetic results at Day 29, by cohort (median [range])
Details
- Database :
- OpenAIRE
- Accession number :
- edsair.doi.dedup.....761803ef4b2434e7ff2418ba535f26e5